TY - JOUR
T1 - Diagnostic benefits of adding EspC, EspF and Rv2348-B to the QuantiFERON Gold In-tube antigen combination
AU - Villar-Hernández, R.
AU - Blauenfeldt, T.
AU - García-García, E.
AU - Muriel-Moreno, B.
AU - De Souza-Galvão, M. L.
AU - Millet, J. P.
AU - Sabriá, F.
AU - Sánchez-Montalvá, A.
AU - Ruiz-Manzano, J.
AU - Pilarte, J.
AU - Jiménez, M. A.
AU - Centeno, C.
AU - Martos, C.
AU - Molina-Pinargote, I.
AU - González-Díaz, Y. D.
AU - Santiago, J.
AU - Cantos, A.
AU - Casas, I.
AU - Guerola, R. M.
AU - Prat, C.
AU - Andersen, P.
AU - Latorre, I.
AU - Ruhwald, M.
AU - Domínguez, J.
N1 - Funding Information:
This work was supported by: (i) a grant from the Instituto de Salud Carlos III (PI16/01912 and PI18/00411), integrated in the Plan Nacional de I + D + I and co-funded by the ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); and (ii) a grant from the Sociedad Española de Neu-mología y Cirugía Torácica (project 25/2016; SEPAR; Barcelona, Spain). ASM was supported by a postdoctoral grant “Juan Rodés” (JE18/00022) from Instituto de Salud Carlos III through the Ministry of economy and competitiveness, Spain.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/8/6
Y1 - 2020/8/6
N2 - Interferon (IFN)-γ release assays (IGRAs) are used to diagnose latent tuberculosis (TB) infection (LTBI). To improve the accuracy of these tests, different approaches, such as alternative cytokine detection and using different antigens, are considered. Following this purpose, this study aims to evaluate the addition of EspC, EspF and Rv2348-B to those present in the QuantiFERON-TB Gold In-Tube (QFN-G-IT). We included 115 subjects: 74 active TB patients, 17 LTBI individuals and 24 healthy controls. Whole blood samples were collected in QFN-G-IT and in-house tubes containing different combinations of EspC, EspF and Rv2348-B, together with ESAT-6, CFP-10, and TB7.7. After overnight incubation at 37 ºC, plasma was harvested and IFN-γ quantified. IFN-γ levels in the QFN-G-IT and in-house tubes correlated very good (Spearman Rho(r) > 0.86). In-house antigen combinations distinguished healthy individuals from those with active TB and LTBI (specificities and sensitivities higher than 87.5% and 96.3%, respectively [AUC > 0.938]). Adding EspC, EspF and Rv2348-B, increased the sensitivity of the test, being the addition of EspC and Rv2348-B the combination that yielded a higher sensitivity with no specificity loss. Addition of these antigens could improve diagnosis in patients with impaired or immature immune response who are at high risk of developing TB.
AB - Interferon (IFN)-γ release assays (IGRAs) are used to diagnose latent tuberculosis (TB) infection (LTBI). To improve the accuracy of these tests, different approaches, such as alternative cytokine detection and using different antigens, are considered. Following this purpose, this study aims to evaluate the addition of EspC, EspF and Rv2348-B to those present in the QuantiFERON-TB Gold In-Tube (QFN-G-IT). We included 115 subjects: 74 active TB patients, 17 LTBI individuals and 24 healthy controls. Whole blood samples were collected in QFN-G-IT and in-house tubes containing different combinations of EspC, EspF and Rv2348-B, together with ESAT-6, CFP-10, and TB7.7. After overnight incubation at 37 ºC, plasma was harvested and IFN-γ quantified. IFN-γ levels in the QFN-G-IT and in-house tubes correlated very good (Spearman Rho(r) > 0.86). In-house antigen combinations distinguished healthy individuals from those with active TB and LTBI (specificities and sensitivities higher than 87.5% and 96.3%, respectively [AUC > 0.938]). Adding EspC, EspF and Rv2348-B, increased the sensitivity of the test, being the addition of EspC and Rv2348-B the combination that yielded a higher sensitivity with no specificity loss. Addition of these antigens could improve diagnosis in patients with impaired or immature immune response who are at high risk of developing TB.
UR - http://www.scopus.com/inward/record.url?scp=85089151067&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-70204-w
DO - 10.1038/s41598-020-70204-w
M3 - Article
C2 - 32764560
AN - SCOPUS:85089151067
SN - 2045-2322
VL - 10
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 13234
ER -